PPAR␣ is a nuclear receptor that controls lipid and glucose metabolism and exerts antiinflammatory activities. The factors regulating human PPAR␣ (hPPAR␣) gene expression remain largely unexplored. To study the mechanisms controlling hPPAR␣ expression, the hPPAR␣ gene promoter was identified and characterized. First, an alternatively spliced exon within the 5-untranslated region of the hPPAR␣ gene was identified by RT-PCR. Next, the transcription start site was mapped and the hPPAR␣ gene promoter was cloned and functionally analyzed. Because PPAR␣ levels are elevated in tissues expressing the hepatocyte nuclear factor-4 (HNF4), such as liver, the regulation of hPPAR␣ by HNF4 was examined. Transient transfections in HepG2 and Cos cells showed that HNF4 enhances hPPAR␣ promoter activity. 5-Deletion and mutation analysis of the hPPAR␣ promoter identified a regulatory element (RE) consisting of a degenerate hexamer repeat with a single nucleotide spacer (direct repeat 1), termed ␣HNF4-RE. Gel shift assays demonstrated that HNF4 binds to this ␣HNF4-RE. Furthermore, HNF4 increased the activity of a heterologous promoter driven by two copies of the ␣HNF4-RE. The nuclear receptor COUP-TFII also bound this site and down-regulated basal as well as HNF4-induced hPPAR␣ promoter activity. Finally, PPAR␣ was shown to bind the ␣HNF4-RE, leading to an induction of PPAR␣ expression in hepatocytes. In summary, the organization of the 5-flanking and untranslated region of the hPPAR␣ gene was characterized and the hPPAR␣ promoter region has been identified.
IS a ligand-activated transcription factor belonging to the nuclear receptor superfamily that regulates gene transcription by heterodimerizing with RXR. PPAR␣/RXR heterodimers bind to PPAR response elements (PPREs) consisting of a direct repeat of the core AGGTCA sequence spaced by 1 or 2 bp [direct repeat 1 or 2 (DR1 or DR2)] preceded by a 5Ј-A/T-rich flanking sequence (1) . In addition, PPAR␣ represses gene transcription by interfering with the nuclear factor B (NFB) and activating protein 1 (AP1) signaling pathways in a DNA binding-independent fashion (2) .
PPAR␣-mediated transcriptional regulation of target genes is tightly controlled by ligand activation. Fatty acid (FA) derivatives and the hypolipidemic fibrates are natural and synthetic PPAR␣ ligands, respectively (3) . PPAR␣ mediates the action of fibrates on plasma lipid levels by regulating the transcription of genes controlling lipoprotein metabolism (4) . Moreover, PPAR␣ is a pivotal modulator of intracellular lipid metabolism by regulating the gene expression of proteins involved in FA uptake, FA esterification, FA entry into the mitochondria, peroxisomal and mitochondrial FA catabolism, and ketone body synthesis (1) . In addition to intra-and extracellular lipid metabolism, glucose and energy homeostasis as well as body weight were also reported to be influenced by PPAR␣ activators (5, 6) . Furthermore, PPAR␣ is an important regulator of vascular inflammation. PPAR␣ inhibits the expression of various inducible factors implicated in the promotion of a local inflammatory response within the developing atherosclerotic plaque (2) . In addition, PPAR␣ regulates the expression of lipoprotein receptors and cholesterol transporters involved in the reverse cholesterol transport pathway in macrophages (7, 8) . PPAR␣ activators reduce plasma concentrations of inflammatory Abbreviations: AP1 or 2, Activating protein 1 or 2; AAP, abridged anchor primer; BAC, bacterial chromosomal clone, COUP-TFII, chicken ovalbumin upstream promotertranscription factor II; DR1, direct repeat-1, FA, fatty acid; HNF4, hepatocyte nuclear factor 4; HNF4-RE, HNF4 regulatory element; NFB, nuclear factor B; PPRE, PPAR response element; RACE, rapid amplification of cDNA ends; RNase, ribonuclease; TK, thymidine kinase; UTR, untranslated region.
cytokines in vivo (9, 10) and reduce the progression of coronary atherosclerosis in humans (11) (12) (13) (14) .
In addition to ligand activation, transcriptional control of PPAR␣ target genes depends on its expression levels. High levels of PPAR␣ expression are observed in tissues with elevated FA catabolic rates, such as liver, heart, kidney, muscle, and the large intestine (15) (16) (17) . In rodents, PPAR␣ is regulated by stress (18) and by different hormones, such as GH, glucocorticoids, insulin, and leptin (19) (20) (21) (22) . PPAR␣ expression oscillates diurnally (18) , is diminished with age (23) , and is induced during brown adipocyte differentiation (24) . Furthermore, starvation increases PPAR␣ expression levels in liver leading to changes in mRNA levels of PPAR␣ target genes (25) . Low PPAR␣ mRNA levels result in decreased PPAR␣ activity in pancreatic islets of obese Zucker diabetic (fa/fa) rats (22) , in rat cardiomyocytes during cardiac hypertrophy (26) , in livers of male Syrian hamsters upon lipopolysaccharide administration (27) , and in intestinal epithelial cells during hypoxia (28) . Moreover, PPAR␣ expression levels correlate with human apo AI gene induction in response to fibrate treatment as demonstrated in human apo AI transgenic mice crossed with PPAR␣-deficient mice (29) .
However, to date, studies addressing the regulation of PPAR␣ gene expression have been largely performed either in rodent cells or in animal models. Although the regulation of PPAR␣ expression in humans remains largely unknown, the observation that hepatic PPAR␣ mRNA levels vary significantly among individuals (30, 31) suggests that PPAR␣ is also regulated at the transcriptional level in humans. Indeed, hPPAR␣ mRNA levels are induced during monocyte differentiation into macrophages (32) , and high glucose concentrations up-regulate PPAR␣ gene expression in human macrophages from healthy control subjects as well as from type 2 diabetic patients (33) .
To understand the molecular mechanisms governing PPAR␣ regulation, we decided to identify and functionally characterize the 5Ј-flanking region of the hPPAR␣ gene. In the present manuscript the transcription start site was determined, and the upstream 5Ј-flanking region of the hPPAR␣ gene was identified and cloned and its transcriptional activity was examined. 1 In the course of these studies the sequence of the 5Ј-untranslated region (UTR) of the hPPAR␣ gene was completed and an alternatively spliced exon within the 5Ј-UTR of the gene was identified. Finally, hPPAR␣ promoter activity was shown to be regulated by the nuclear receptors hepatocyte nuclear factor 4 (HNF4), chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII), and PPAR␣ itself.
RESULTS

Characterization of the 5-UTR Structure of the hPPAR␣ Gene and Identification of an Alternatively Spliced 5-UTR Variant
The hPPAR␣ gene contains at least eight exons in which exons 1 and 2 and the 5Ј-end of exon 3 and the 3Ј-end of exon 8 are not translated (34, 35) . The aim of our study was to determine the 5Ј-UTR structure of the hPPAR␣ gene and to identify and characterize the hPPAR␣ promoter. To identify noncoding exons within this region, different primers were designed and PCRs were carried out on reverse transcribed human liver RNA from two different subjects. Using this approach, a novel exon was discovered. When PCR was performed using a primer designed at the 3Ј-end of exon 2 (primer 13, Fig. 1A ) and a primer hybridizing the 3Ј-end of exon 1 (primer 15C, Fig. 1A ), a fragment of 158 bp containing both exon 1 and exon 2 was amplified (Fig. 1B, left) , as expected. Additionally, a second fragment 150 bp longer was repeatedly coamplified even at stringent PCR conditions. Similar results were obtained with four other human liver and adipose tissue mRNA samples (data not shown), indicating that the unexpected additional PCR product corresponded to a rather common transcript. Cloning and sequencing of this PCR fragment revealed the presence of 156 bp of novel sequence downstream of the sequence previously known as exon 1 (Fig. 1C) . Furthermore, when PCR was performed using a primer within the novel sequence (primer IP3) and the exon 1-specific primer 15C, a fragment was amplified, further indicating the existence of this additional exon (Fig. 1B, right) . The novel sequence was located between exon 1 and 2 in a bacterial artificial chromosome (BAC) clone containing the hPPAR␣ gene and was flanked by ag/gt consensus acceptor and donor splice sites, respectively (Fig. 1C) . The newly identified exon was named exon 1b, by analogy to the nomenclature used for the alternatively spliced exon present in the 5Ј-UTR of the mouse PPAR␣ gene (36) , whereas the previously known exon 1 was renamed exon 1a (Fig. 1A) . In addition, when 5Ј-RACE (rapid amplification of cDNA ends) reactions were carried out using primer IP3 located in exon 1b as gene-specific primer, a fragment covering the novel exon plus a sequence corresponding to exon 1a was amplified (data not shown), corroborating the existence of a second alternative transcript containing exon 1b in addition to exon 1a. This suggests that exon 1b is spliced out alternatively giving rise to two different transcripts with distinct 5Ј-UTRs (Fig. 1A) . Thus, both mouse and human PPAR␣ (hPPAR␣) genes display a similar 5Ј-UTR genomic organization. However, the noncoding exons do not show a significant degree of sequence homology among species (38% for exon 1a and 29% for exon 1b). 1 The sequence data for the hPPAR␣ exon 1a, 1b, and promoter have been submitted to the GenBank database under GenBank accession numbers AF323915, AF323916, and AF323917, respectively. Oligonucleotides used for RT-PCR analysis are indicated by arrows. B, RT-PCR analysis on human liver RNA isolated from two different subjects. Total RNA was extracted, reverse transcribed, and amplified using primers 15C and 13 (left) or 15C and IP13 (right). ϪPCR corresponds to a PCR carried in the absence of RT product. C, Genomic sequence corresponding to the alternatively spliced exon 1b. Oligonucleotides IP3 and IP7 used for 5Ј-RACE analysis are indicated by arrows. The acceptor and donor splice sites are depicted in bold. Nucleotides in uppercase and lowercase letters correspond to exon and intron sequences, respectively. A, Sequence corresponding to exon 1a in the 5Ј-UTR region. The oligonucleotides YGSP1, IP24, IP18, and 5-GSP used for 5Ј-RACE, RNase protection analysis, and cloning are indicated by arrows. The donor splice site is depicted in bold lowercase. The previously reported 5Ј-UTR sequence (37) is indicated in italics. Transcription start site (ϩ1) is shown by an arrow. The sequence in bold uppercase represents a region showing 88% homology with both rat and mouse 5Ј-UTRs (see text for of the 5Ј-RACE products on an agarose gel. Total RNA from human liver was reverse transcribed and the cDNA was poly-(dC) tailed with terminal deoxynucleotide transferase (TdT) as described in Materials and Methods. dC-tailed cDNA (TdTϩ) or untailed cDNA (TdTϪ) were amplified using an universal primer (AAP) and a gene-specific primer (IP18). C, Schematic representation of the probe used for RNase protection analysis. A genomic DNA fragment (Ϫ22 to ϩ213) was amplified with oligonucleotides IP24 and IP18 (depicted in panel A) and cloned into pBluescript SK ϩ . Subsequently an antisense RNA probe was transcribed. The size of the
Determination of the Transcription Start Site
To determine the hPPAR␣ transcription start site, 5ЈRACE-PCR analysis was performed. Genomic sequence upstream of the previously reported exon 1a sequence (37) was obtained by primer walking the BAC clone containing the hPPAR␣ gene. Despite the overall low degree of homology shown by the PPAR␣ 5Ј-UTRs among different species, a sequence of around 60 bp was found to be 88% homologous to a region close to the transcription start site in the mouse PPAR␣ 5Ј-UTR ( Fig. 2A) . This prompted us to examine whether the transcription start site in the human gene could also be upstream of this region. Accordingly, a primer close to that sequence (primer IP18, Fig. 2A ) was used as gene-specific primer in a 5Ј-RACE-PCR. A 213-bp DNA fragment was amplified from human liver RNA (Fig. 2B ) and subsequently sequenced. The most 5Ј-nucleotide before the poly-dC tail introduced by the 5Ј-RACE procedure mapped to a T and was designated as nucleotide ϩ1 ( Fig. 2A) . Similar results were obtained when a different gene-specific primer (primer 5-GSP) was used in the 5Ј-RACE-PCR (data not shown). To confirm the results of the 5Ј-RACE experiments, ribonuclease (RNase) protection analysis was performed. RNase mapping with a 337-nucleotide labeled cRNA probe complementary to bp Ϫ22 to ϩ213 (Fig. 2C ) gave a major protected band of 213 bp ( Fig. 2D) , thus confirming the transcription start site that had been identified by 5Ј-RACE. These data indicate that exon 1a is considerably longer than the partially sequenced exon 1 that had been previously reported (34, 35, 37) and than the exon 1a identified in the mouse PPAR␣ gene (36) .
Cloning and Analysis of the 5-Flanking Region of the hPPAR␣ Gene
To identify potential binding sites for transcription factors that may be important in the regulation of hPPAR␣ gene expression, 1.6 kb of hPPAR␣ sequence upstream of the transcription start site were cloned. No consensus TATA or CCAAT boxes were found within the first 100 bp, although a CCAAT box was observed at Ϫ472 bp (Fig. 3) . Furthermore, this region possesses the characteristics of a TATA-less promoter, namely, GC-rich sequences and multiple putative Sp1 binding sites. Computer-assisted analysis (38) revealed several potential transcription factor binding sites including AP2, Egr-1, Egr-2, E box, NFB, and MZF-1 among others (Fig. 3 ).
Functional Characterization of the hPPAR␣ Promoter
To determine the ability of hPPAR␣ 5Ј-flanking region to drive basal transcriptional activity, sequences were fused to a luciferase reporter gene. Because hPPAR␣ is highly expressed in liver (17), the 1,664-bp promoter-containing plasmid, p␣(H-H)-pGL3, was transiently transfected into human HepG2 hepatoma cells. Activity of this construct was about 8-fold the activity of the parental promoterless construct (pGL3 basic) in these cells (Fig. 4) . Next, the promoter activity of different 5Ј-deletion constructs was evaluated. Deletion from Ϫ1,664 to Ϫ1,206 did not significantly affect the promoter activity. Truncation to Ϫ648 significantly reduced the luciferase activity in HepG2 cells. By contrast, in agreement with hPPAR␣ tissue-selective expression, luciferase activities of the p␣(H-H)-pGL3 construct and its 5Ј-deletion mutants were only 2-fold higher than pGL3 basic in Cos-1 cells, a cell line that does not express PPAR␣. These experiments suggest that these cells are devoid of the factors driving basal hPPAR␣ expression compared with HepG2 cells. The shortest construct, p␣(P-H)-pGL3, containing the GC-rich proximal promoter was only 2-fold more active relative to pGL3 basic vector in both cell lines compared with the 6-fold activity shown by the p␣(E-H)-pGL3 construct, which suggests that sequences between Ϫ536 and Ϫ1,664 may contain binding sites for key transcription factors driving basal hPPAR␣ gene expression.
Identification of a Functional HNF4 Regulatory Element (HNF4-RE) in the hPPAR␣ Promoter
Because hPPAR␣ is highly expressed in liver and the hPPAR␣ 5Ј-flanking region shows significant promoter activity in HepG2 cells, the regulation of hP-PAR␣ promoter activity by HNF4, a nuclear receptor that is abundantly expressed in liver, was examined. To this purpose, transient transfection studies were performed with the p␣(H-H)-pGL3 construct in HepG2 cells. In the presence of increasing concentrations of HNF4, hPPAR␣ promoter activity was induced in a dose-dependent fashion (Fig. 5A ). To localize the region that confers HNF4 responsiveness within the hPPAR␣ promoter, cotransfection assays were repeated with a series of 5Ј-deletion hPPAR␣ promoter constructs ( the hPPAR␣ promoter revealed two potential hexamer binding sites separated by a single nucleotide between nucleotide Ϫ1,492 to Ϫ1,483 (Fig. 3) , conforming to the DR1 response elements for HNF4 (HNF4-RE). To unequivocally characterize the imperfect DR1 as an HNF4 response element, HepG2 and Cos cells were transfected with a hPPAR␣ promoter construct bearing two nucleotide mutations in the 5Ј-hexamer of the DR1 element, p␣(H-H)␣HNF4-REmut-pGL3. In contrast to the wild-type promoter construct p␣(H-H)-pGL3, the mutated promoter was not influenced by HNF4 cotransfection in both cell lines (Fig. 5C ), thus demonstrating that the hPPAR␣ HNF4-RE (␣HNF4-RE) indeed confers HNF4 response to the hPPAR␣ promoter.
Binding Analysis of HNF4 to the DR1 Element
To demonstrate direct binding of HNF4 to the ␣HNF4-RE, EMSAs were performed with a radiolabeled DR1 oligonucleotide probe and in vitro translated HNF4 proteins. As shown in Fig. 6 , HNF4 bound the ␣HNF4-RE (Fig. 6A, lane 4) and the well characterized C3P site present in the apo CIII promoter (39) with similar efficacy (Fig. 6A, lanes 2 and 4) . DNA binding was almost completely abolished when two-point mutations were introduced into the ␣HNF4-RElabeled oligonucleotide (GCAGCAAAGTTCA instead of GGGGCAAAGTTCA where the underlined letters indicate the mutated nucleotides) (Fig. 6A, lane 5) .
Furthermore, the specificity of the HNF4-DR1 interaction was demonstrated by competition studies. Inhibition of formation of the complex was shown by the addition of increasing concentrations of either the unlabeled ␣HNF4-RE (Fig. 6B , lanes 3-5) or C3P (Fig. 6B , lanes 9-11) oligonucleotides, whereas competition with an equivalent amount of unlabeled mutated ␣HNF4-RE did not significantly displace the labeled wild-type element (Fig. 6B , lanes 6-8).
The ␣HNF4-RE Confers HNF4 Responsiveness to a Heterologous Promoter
To explore the activation of the ␣HNF4-RE by HNF4 in the context of a heterologous promoter, cotransfection studies were performed with the ␣HNF4-REx2S-TKpGL3 construct, which contains two copies of the DR1 in the sense orientation in front of the thymidine kinase (TK) promoter (Fig. 7A ). Upon cotransfection of HNF4 into both HepG2 and RK13 cells, the ␣HNF4-REx2S-TKpGL3 transcriptional activity was significantly enhanced (Fig. 7 , B and C). By contrast, the reporter activity of a similar heterologous promoter construct containing two copies of the mutated ␣HNF4-RE was not influenced by HNF4 cotransfection (Fig. 7C) . Taken together, these data show that the DR1 site is a bona fide HNF4-RE that mediates HNF4 induction of hPPAR␣ promoter activity. 
COUP-TFII Binds the ␣HNF4-RE and Represses Basal and HNF4-Induced hPPAR␣ Promoter Activity
DR1 elements can be recognized not only by HNF4, but also by other members of the nuclear receptor superfamily, including the transcription factor COUP-TFII, also known as apo A-1 regulatory protein 1 or ARP1 (40) . In addition, COUP-TFII has been shown to actively repress or modulate the effects of HNF4 on the transcription of several genes in liver (39, (41) (42) (43) (44) . Therefore, the ability of COUP-TFII to bind the ␣HNF4-RE was evaluated by gel shift analysis. COUP-TFII proteins bound to the radiolabeled ␣HNF4-RE probe, and competition with 50-fold molar excess of unlabeled ␣HNF4-RE oligonucleotide completely inhibited the formation of the COUP-TFII -DNA complex (Fig. 8A, lanes 2 and 3) .
The influence of COUP-TFII on the hPPAR␣ promoter activity was then investigated by cotransfection experiments in HepG2 and Cos cells. Transient transfection of COUP-TFII alone decreased the activity of the hPPAR␣ promoter construct containing the ␣HNF4-RE site in both HepG2 and Cos cells (Fig. 8B) . As previously observed, upon cotransfection of HNF4, hPPAR␣ promoter activity was induced in both cell lines. However, overexpression of COUP-TFII in the presence of HNF4 abrogated the HNF4-induced transcriptional activity. On the contrary, when identical experiments were performed with a promoter construct bearing a mutation in the ␣HNF4-RE, promoter activity was not affected by cotransfection of either COUP-TFII or HNF4 alone or added together (Fig. 8B ). These data demonstrate that the repression of the PPAR␣ promoter by COUP-TFII and the antagonism of the HNF4 induction are dependent on the ␣HNF4-RE. Altogether these results indicate that COUP-TFII negatively regulates PPAR␣ gene transcription.
hPPAR␣ Binds the ␣HNF4-RE and Regulates Its Own Expression
Next, direct binding of PPAR␣/RXR␣ heterodimers to the hPPAR␣ ␣HNF4-RE was examined. To this purpose, gel shift analysis was performed with the radiolabeled ␣HNF4-RE probe and in vitro translated PPAR␣ and RXR␣ proteins. PPAR␣/RXR␣ heterodimers bound the ␣HNF4-RE oligonucleotide (Fig.  9A, lane 2) . DNA binding could be competed with increasing amounts of unlabeled ␣HNF4-RE oligonucleotide (Fig. 9A, lanes 3-5) , whereas incubation with a mutated ␣HNF4-RE oligonucleotide did not compete for binding (Fig. 9A, lanes 6-8) .
To determine the effect of PPAR␣ on hPPAR␣ promoter activity, transient transfection assays were performed using the hPPAR␣ promoter construct containing the ␣HNF4-RE. Cotransfection of PPAR␣ induced hPPAR␣ reporter activity approximately 2-fold, an effect that was enhanced in the presence of Wy 14,643. By contrast, no effect by either PPAR␣ or its ligand could be observed when a construct containing the mutated ␣HNF4-RE was employed, indicating that an intact ␣HNF4-RE site is required for the PPAR␣-mediated induction. To investigate whether the ␣HNF4-RE could function as a PPRE in front of a heterologous promoter, transient transfection assays were performed using the ␣HNF4-REx2S-TKpGL3 construct (Fig. 9C) . Incubation of cells with Wy 14,643 in the presence of cotransfected PPAR␣ resulted in a 5-fold activation of the ␣HNF4-REx2S-TKpGL3 construct, indicating that the ␣HNF4-RE site is a functional PPRE. The region spanning 1,664 bp of promoter and the first 83 bp of exon 1a was progressively deleted from its 5Ј-end, fused to the pGL3 basic vector, and transfected into the indicated cell types as described in Materials and Methods. Values (mean Ϯ SD) represent firefly luciferase activity normalized relative to a Renilla luciferase transfection internal control. Luciferase activities are shown relative to the activity of the pGL3 basic vector, which was arbitrarily set to 1.
Fig. 5. HNF4-Mediated Transcriptional Regulation of hPPAR␣ via a DR1 Element
A, HNF4 increases hPPAR␣ promoter activity. HepG2 cells were transfected with the indicated reporter construct in the presence or absence of increasing amounts (3, 10, and 30 ng) of the HNF4 expression plasmid. When the hPPAR␣ promoter plasmid was not cotransfected, pGL3 basic empty vector was added to the transfection mixture. Relative luciferase activities are shown as described in Fig. 4 . B, Deletion analysis of the hPPAR␣ promoter. HepG2 cells were transfected with the indicated Finally, to analyze whether hPPAR␣ mRNA expression is regulated by PPAR␣ agonists, primary hepatocytes isolated from human liver were cultured for 24 h in medium containing fenofibric acid. hPPAR␣ mRNA levels were markedly up-regulated upon treatment with fenofibric acid (Fig. 9D) . Taken together, these data show that PPAR␣ positively autoregulates its expression.
DISCUSSION
PPAR␣ is a transcription factor that regulates lipid, glucose, and energy homeostasis and controls body weight and vascular inflammation. Thus, PPAR␣ may play a modulatory role in the onset and evolution of different metabolic and vascular disorders such as dyslipidemia, obesity, insulin resistance, and atherosclerosis (1) . Dysregulation of PPAR␣ expression may contribute to the development of these disorders as well as the response to its fibrate agonists. Indeed, PPAR␣ expression levels have been shown to influence its transcriptional activity as well as the response to fibrate treatment in rodents (22, (25) (26) (27) . However, the study of the molecular mechanisms governing PPAR␣ regulation in humans has not been addressed to date.
To study PPAR␣ regulation in humans, we characterized the 5Ј-flanking region of the hPPAR␣ gene and 
Fig. 6. HNF4 Binds the ␣HNF4-RE
A, HNF4 binds the ␣HNF4-RE and C3P oligonucleotide probes with similar efficacy. Autoradiograph of EMSA performed on end-labeled oligonucleotides (probe) using in vitro translated HNF4. B, Competition experiments were performed in the presence of 1-, 10-, and 100-fold molar excess of the indicated unlabeled oligonucleotides on a ␣HNF4-RE radiolabeled probe.
identified the hPPAR␣ promoter. The genomic organization of hPPAR␣ was recently reported (34, 35) . The hPPAR␣ gene contains at least eight exons in which exons 1 and 2, the 5Ј-end of exon 3, and the 3Ј-end of exon 8 are not translated (34, 35) . As an initial step in our study, the 5Ј-UTR of the hPPAR␣ gene was further characterized, resulting in the completion of the 5Ј-end sequence of exon 1, renamed exon 1a, and in the identification of an alternatively spliced 5Ј-variant. An alternatively spliced exon in the mouse PPAR␣ 5Ј-UTR has been previously reported (36) . However, alignment of both mouse and human 5Ј-UTR sequences revealed no significant degree of homology between them despite the coding exons being very similar between species.
The transcription start site of the hPPAR␣ gene was mapped. The proximal promoter of the hPPAR␣ gene contains no typical TATA or CCAAT boxes and has a high GC content, including several consensus Sp1 sites, features that are also present in the mouse PPAR␣ promoter (36) . Excluding the proximal GC-rich region, both promoters do not show a high degree in sequence homology (ϳ40%). However, only a small fragment of the mouse PPAR␣ promoter has been sequenced to date (36) . This sequence disparity in both the 5Ј-UTR and the promoter regions may indicate that PPAR␣ gene expression among species could be regulated in a different manner although sufficient data to establish a thorough comparison between species are lacking at this stage.
Computer-assisted analysis of the hPPAR␣ promoter sequence identified various putative transcription factor binding sites, such as sites for members of the early growth response (Egr) gene family, which are involved in the induction of monocytic differentiation (45) . Egr proteins could thus be involved in the upregulation of hPPAR␣ expression upon monocyte differentiation into macrophages (32) although further studies are needed to confirm this hypothesis. Furthermore, potential sites for NFB and AP1, factors involved in the transduction of several cytokine and proinflammatory signals, as well as for the myeloid Fig. 7 . The ␣HNF4-RE Confers HNF4 Responsiveness to a Heterologous Promoter A, Schematic representation of the ␣HNF4-REx2S-TKpGL3 and the ␣HNF4-REmutx2S-TKpGL3 constructs. The bases mutated in ␣HNF4-REmutx2S-TKpGL3 are underlined. B, The ␣HNF4-REx2S-TKpGL3 construct was transfected in either HepG2 or RK13 cells in the presence or absence of HNF4. When the ␣HNF4-RE heterologous construct was not cotransfected, TK-pGL3 empty vector was added to the transfection mixture (Ϫ). Data represent the mean Ϯ SD of the firefly luciferase activity normalized relative to a Renilla luciferase transfection internal control. Relative luciferase activities are shown as fold induction of the activity of TK-pGL3 in the absence of HNF4, which was arbitrarily set to 1. C, HepG2 cells were transfected with either the ␣HNF4-REx2S-TKpGL3 or the ␣HNF4-REmutx2S-TKpGL3 constructs in the presence or absence of HNF4. The data represent the mean Ϯ SD of the firefly luciferase activity normalized relative to a Renilla luciferase transfection internal control and are shown as described in Fig. 5B . zinc finger gene, MZF-1, were found in the hPPAR␣ promoter. PPAR␣ inhibition of NFB-and AP1-induced expression of inflammatory response genes (46) lies at the basis of its antiinflammatory activities. It is tempting to speculate that hPPAR␣ expression, in its turn, is controlled by inflammatory cytokines. Because rodent PPAR␣ mRNA levels are increased by glucocorticoids (20, 21) , putative GR response elements were searched for. No obvious GR response element could be detected within the hPPAR␣ regulatory region analyzed; however, regulation studies in human tissues or cell lines would be necessary to determine whether hPPAR␣ expression is also modulated by glucocorticoids in humans.
HNF4 is a nuclear receptor that plays a key role in liver-specific gene expression (47) and is required for mammalian hepatocyte differentiation and for normal metabolic regulation in liver (48) . HNF4 is expressed at high levels in liver, kidney, and intestine (47) . It binds as homodimers to DR1-like response elements, thereby modulating the expression of several liverenriched genes encoding apolipoproteins, coagulation factors, serum proteins, proteins of the cytochrome P450 family, and genes involved in FA and glucose metabolism (49) . Regulation of hPPAR␣ by HNF4 is consistent with the tissue-expression pattern shown by PPAR␣. In the present study induction of hPPAR␣ promoter activity by HNF4 is reported. A HNF4-RE was identified at nt Ϫ1,492 to Ϫ1,483 within the hPPAR␣ promoter. This element closely resembles several HNF4-REs found in other genes and the GGGGCA A AGGTCA consensus HNF4 binding site (50) . Moreover, the regulation of PPAR␣ gene expression by HNF4 in vivo in mice was recently demonstrated using HNF4-deficient mice (51) . These mice display significantly lower PPAR␣ mRNA levels compared with the wild-type mice, thus demonstrating that PPAR␣ expression is regulated by HNF4 also in mice. Nevertheless, the promoter experiments performed with the hPPAR␣ promoter indicate that the HNF4 site identified is not responsible for the activity of the hPPAR␣ promoter in liver because the promoter construct lacking this site still possesses a significant activity in HepG2 cells (Fig. 4) . This may suggest that this site binds as well other factors, such as COUP-TF, present in these cells that negatively regulate the hPPAR␣ promoter either as a result of a direct repression of the promoter or due to competition with factors, such as HNF4, for binding to the site. In addition, negative factors may bind to sites located between Ϫ1,664 and Ϫ1,206 bp in the hPPAR␣ promoter. Future studies on the regulation of this promoter will be required to elucidate the factors governing hPPAR␣ gene expression in liver.
Members of the COUP-TF family of orphan nuclear receptors have been reported to bind DR1 sites that are also recognized by HNF4 (52) . COUP-TF actively represses or antagonizes HNF4-mediated transcriptional activation of several genes (39, (41) (42) (43) (44) . COUP-TF II has been shown to play a role in cardiac energy metabolism and heart development (53, 54). In this study, COUP-TFII was also shown to bind the HNF4-RE within the hPPAR␣ regulatory region and to repress both basal and HNF4-induced hPPAR␣ promoter activity. The COUP-TFII antagonism may finely tune HNF4-dependent gene expression. The expression level of a COUP-TFII/HNF4 target gene would therefore depend on the relative concentrations of both transcription factors in a given cell type or during a certain condition. For instance, the age-dependent diminution of apo AI gene expression has been shown to occur at the transcriptional level and to be associated with a decrease in the binding capacity and expression of HNF4 and a parallel increase in COUP-TFII binding and concentration levels (55) . Interestingly, PPAR␣ gene expression is also diminished in aged rats (23) . Further studies are required to demonstrate whether the molecular mechanisms described for the age-dependent decline of apo AI can also explain the decreased expression of PPAR␣ with age.
Finally, PPAR␣ is also capable of binding to the ␣HNF4-RE. Induction of PPAR␣ gene expression by PPAR␣ agonists has been reported in different rodent cell lines (22, 24, 56) . Our data indicate that PPAR␣ agonists, such as fenofibrate, induce hPPAR␣ mRNA levels in primary cultures of human hepatocytes as well as hPPAR␣ promoter activity, suggesting that these effects are exerted at the transcriptional level. Furthermore, induction of hPPAR␣ promoter activity is dependent on the identified ␣HNF4-RE. Autoregulation is a common feature among nuclear receptors. For instance, GRs are regulated by glucocorticoids, and glucocorticoids exert these actions mainly at the level of transcription (57) . AR is another nuclear recep- tor that is autoregulated (58) , and three different ER␣ promoters have been shown to be regulated by estrogens (59) .
The coding exons of the hPPAR␣ gene have been screened for polymorphisms. A leucine-to-valine missense mutation at codon 162 in exon 5 of the hPPAR␣ gene (L162V) was recently identified (34, 35) . This polymorphism shows an enhanced transactivation activity (34) and has been associated with altered plasma lipid and lipoprotein concentrations in type 2 diabetic subjects (34), supporting a role for PPAR␣ in dyslipidemia and diabetes in humans also. Variants have been identified in other exons and introns of the hPPAR␣ gene (Ref. 60 and Flavell, D., I. Pineda Torra, and B. Staels, unpublished observations). However, these polymorphisms either show low frequency in the populations studied or they do not directly affect PPAR␣ activity due to their location in intronic sequences of the gene. Thus, it will be interesting to search for polymorphisms in the promoter sequences of the gene that may affect PPAR␣ expression and function.
Taken together, the 5Ј-flanking region of the hPPAR␣ gene has been characterized, cloned, and functionally studied. HNF4 induces hPPAR␣ expression via a DR1 element present in the hPPAR␣ promoter, whereas this effect is antagonized by the orphan receptor COUP-TFII. In addition, PPAR␣ itself modulates its own expression. Knowledge of the hPPAR␣ promoter structure will allow further studies of the molecular mechanisms governing hPPAR␣ gene regulation.
MATERIALS AND METHODS
DNA Sequencing
Sequencing of a BAC clone containing the hPPAR␣ gene (kind gift of B.Wilkinson; Glaxo Welcome, Research Triangle Park, NC) was performed using the dRhodamine terminator cycle sequencing kit on an ABI Prism 377 DNA sequencer (Perkin-Elmer Corp., La Jolla, CA).
Rapid Amplification of cDNA Ends (5-RACE) PCR and RT-PCR Analysis
Total human liver RNA was isolated using the guanidinium isothiocyanate method (61) . 5Ј-RACE was performed on 1 g total RNA using the 5Ј RACE-System for Rapid Amplification of cDNA Ends kit (Life Technologies, Inc., Gaithersburg, MD) according to the manufacturer's instructions. For the determination of the 5Ј-end of exon 1a, first-strand synthesis of hPPAR␣ cDNA was carried out using the IP7 oligonucleotide (5Ј-CAAGCAGTCCTCCTACCTCAGCCTTCCAAG-3Ј) located in exon 1b (Fig. 1C) as a gene-specific primer. After RNase H treatment and poly(dC)-tailing of the cDNA with a terminal deoxynucleotide transferase, the resulting cDNA (5 l) was amplified in a PCR using the Abridged Anchor Primer (AAP) and the internal gene-specific primer YGSP1 (5Ј-AGTTCT-GAGCTTCTCTTGCCACAAACAGTTGAGTCC-3Ј) located in exon 1a (Fig. 2D) . PCR cycling parameters were as follows: initial denaturation at 95 C for 5 min followed by 35 cycles of 1 min at 95 C, 40 sec at 57 C, and 40 sec at 72 C with a final elongation at 72 C for 3 min. The PCR product was then diluted 100-fold, and the diluted PCR (5 l) was used for a nested PCR under the same conditions described above with the Abridged Universal Amplification Primer (AUAP) (nested to AAP) and oligonucleotide IP18 (5Ј-AGAGTCGCTGCG-GTCCCCAGAC-3Ј) (nested to YGSP1). Oligonucleotides AUAP and AAP were provided in the 5Ј-RACE kit. PCR products were visualized on a 2% agarose gel and sequenced as described above. RT-PCR amplification of the hPPAR␣ 5Ј-UTR was performed as described (31) using oligonucleotides 15C (5Ј-CAGGGCCCTGTCTGCTCTGTGCA-3Ј), 13 (5Ј-CTCTTATCTATGAAGCAGGAAGCACG-3Ј), and IP3.
RNase Protection Analysis
The RNase protection probe used to map the transcription initiation site of the hPPAR␣ gene was amplified by PCR from the BAC-hPPAR␣ clone using oligonucleotides IP24 (5Ј-CGCGGGGCCCGGGGTCTCGGGGTCTCCG-3Ј) and IP18 and cloned into the EcoRV site of pBluescript SK ϩ (Stratagene, La Jolla, CA). After linearizing with XhoI, antisense RNA was transcribed with T3 polymerase using the Maxiscript Kit (Ambion, Inc., Austin, TX) as described by the manufacturer. This 337-nucleotide probe contains cRNA complementary to the hPPAR␣ 5Ј-flanking region (bp Ϫ22 to ϩ213) and to the polylinker of the pBluescript SK ϩ vector (102 bp). RNase protection analysis was carried out using the Hybspeed RNase protection Kit (Ambion, Inc.) as described previously (31) .
Real-Time PCR mRNA Quantification
PPAR␣ and 28S mRNAs were quantified by reverse transcription followed by Real-Time PCR using a LightCycler (Roche Diagnostics, Meylan, France) with oligonucleotide primers specific for hPPAR␣ (5Ј-ATATCTCCCTTTTTGTG-GCTGCTA-3Ј and 5Ј-TCCGACTCCGTCTTCTYGATGA-3Ј) and 28S (62) . Reactions were carried out in a 20-l reaction containing a 500-nM concentration of each primer, 4 mM MgCl 2 , and the LightCycler-FastStart DNA Master SYBR Green I mix as recommended by the manufacturer with the following conditions: 95 C for 8 min, followed by 40 cycles of 10 sec at 95 C, 10 sec at 55 C and 14 sec (for hPPAR␣) or 15 sec (for 28S) at 72 C. hPPAR␣ mRNA levels were normalized to 28S mRNA.
Cloning of the hPPAR␣ Promoter and Construction of Reporter Plasmids
Genomic sequences between Ϫ3,593 and ϩ83 (numbered on the basis of the distance from the transcription initiation site) obtained by direct sequencing of the BAC-hPPAR␣ clone were amplified by PCR using oligonucleotides IP34 (5Ј-GCCAGGAGCAGCCACCAGGGAAATC-3Ј) and 5-GSP (5Ј-AGTCCTCGGTGTGTGTCCTCGCTCCTC-3Ј) from BAC clone DNA. The resulting product was cloned blunt into the EcoRV site of pBluescript SK ϩ (Stratagene). Reporter constructs were generated thereafter by digestion using restriction sites within the hPPAR␣ promoter. The pBS(IP34-5GSP) construct was digested with HindIII or both HindIII and XhoI, and the resulting promoter digestion products were gel purified and cloned into a HindIII or XhoI plus HindIII-digested pGL3 basic plasmid (Promega Corp., Madison, WI), creating the reporter vectors p␣(H-H)-pGL3 and p␣(X-H)-pGL3, respectively. Plasmids p␣(E-H)-pGL3 and p␣(P-H)-pGL3 were generated by digestion of p␣(X-H)-pGL3 with EcoRI plus XhoI or PstI plus XhoI, Klenow fill in of cohesive ends, and subsequent ligation of the obtained blunt ends. ␣HNF4-REx2S-TKpGL3 and ␣HNF4-REmutx2S-TKpGL3 were created by ligating two copies of the corresponding double-stranded oligonucleotides (5Ј-GATCCTGGAGGGTGGGGCAAAGTTC-ACCATAGGTA-3Ј for ␣HNF4-REx2S-TKpGL3 and 5Ј-GATC-CTGGAGGGTGCAGCAAAGTTCACCATAGGTA-3Ј for ␣HNF4-REmutx2S-TKpGL3) in the sense orientation into the BamHI site of TK-pGL3. All constructs were verified by restriction site digestion and sequence analysis. Transcription factor analysis of the promoter was performed using the MatInspector program (http://genomatix.gsf.de/cgi-bin/matinspector/ matinspector.pl).
Site-Directed Mutagenesis
To create p␣(H-H)␣HNF4-REmut-pGL3, mutation of the ␣HNF4-RE was generated using the QuikChange SiteDirected Mutagenesis Kit (Stratagene) and oligonucleotide (5Ј-GGTGTCTGGAGGCTGCAGCAAAGTTCACCATAG-3Ј) and its complementary oligonucleotide according to the manufacturer's recommendations.
Cell Culture and Transient Transfection Assays
Human liver specimens were collected for transplantation at the Moscow Center, and hepatocytes were obtained by a two-step collagenase perfusion as previously described (63) . Donors were physically healthy subjects who died after traumatic brain injury. Permission to use the remaining untransplanted donor liver for scientific research purposes was obtained from the Ministry of Health of the Russian Federation. After 20 h of culture the medium was discarded and 250 M fenofibric acid (Laboratories Fournier, Daix, France) or vehicle was added at the indicated concentration in serum-free medium for 24 h. HepG2 (human hepatoblastoma), RK13 (rabbit kidney), and Cos cells were cultured as previously described (31) . HepG2 (10 5 ), RK13 (8 ϫ 10 4 ), and Cos (4 ϫ 10 4 ) cells were transfected using the cationic lipid RPR 120535B (kind gift of Aventis, Vitry, France) as described previously (64) . One hundred nanograms of the indicated pGL3 basic firefly luciferase reporter constructs or 10 ng of the TK-pGL3 reporters were cotransfected with or without 30-50 ng of pSG5-hHNF4␣1 (termed HNF4 throughout this manuscript, kindly provided by B. Laine), pcDNA3-COUP-TFII [subcloned from pMT2-COUP-TFII (65) into pcDNA3] or pSG5-hPPAR␣, and either 20 ng or 5 ng of the internal control Renilla luciferase reporter plasmids, pRL-Null (when basal promoter activities of the different deletion constructs were examined) (Promega Corp.) and pRL-Cϩ (for the remaining transfection experiments), respectively. pRL-Cϩ was obtained by replacing the luc ϩ cassette in pGL3-Cϩ (Promega Corp.) with the Renilla gene. When either HNF4 or COUP-TFII plasmid was not cotransfected, pSG5 (Stratagene) or pcDNA3 (Invitrogen) empty vectors were added to the transfection mixture. Luciferase activity was assayed 36 h later using the Dual-Luciferase Reporter Assay System (Promega Corp.). Transfections were carried out in triplicate, and each experiment was repeated at least twice.
EMSAs
HNF4, COUP-TFII, PPAR␣, and RXR␣ were synthesized in vitro using the TNT Quick Coupled Transcription/Translation System (Promega Corp.). Double-stranded oligonucleotides were end-labeled with [␥-32 P]ATP by using T4-polynucleotide kinase. Proteins (2 l) were incubated for 15 min at room temperature in a total volume of 20 l with 2.5 g poly (dI-dC) and 1 g herring sperm DNA in binding buffer (10 mM HEPESNaOH, pH 7.8; 100 mM NaCl; 0.1 mM EDTA; 10% glycerol; 1 mg/ml BSA; and 0.5 mM dithiothreitol) before the radiolabeled probe (0.5 ng) was added. Binding reactions were further incubated for 15 min and resolved by 4% nondenaturing polyacrylamide gel electrophoresis in 0.25ϫ Tris-borate-EDTA buffer at room temperature. For competition experiments, increasing amounts of unlabeled oligonucleotide ␣HNF4-RE, ␣HNF4-REmut, or C3P (39) were included in the binding reaction just before addition of the labeled oligonucleotide.
